[Disclosure] Celltrion (068270) Secures South Korean MFDS Marketing Authorization for ‘Actemra Biosimilar (CT-P47)’ Avtozma Subcutaneous Injection

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-02-13

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion has obtained final marketing authorization from the South Korean Ministry of Food and Drug Safety (MFDS) for ‘Avtozma Subcutaneous Injection’ (a biosimilar to Actemra), providing a therapeutic option for patients with rheumatoid arthritis in South Korea.

📊 1. [Key Disclosure Content & Key Metrics Summary]

• Authorized Brand & Substance: Avtozma Subcutaneous Injection (CT-P47, Actemra biosimilar) / Active substance: Tocilizumab.
• Approved Indication: Rheumatoid arthritis.
• Key Administrative Timeline:
  • Application Date: February 28, 2024
  • Approval Date: February 12, 2025
• Regulatory Body: South Korean Ministry of Food and Drug Safety (MFDS)
• Authorized Status: Approved for domestic marketing of Avtozma Subcutaneous Injection for the specified indication of rheumatoid arthritis.

📈 2. [Expert View: What This Disclosure Means for Investors]

• Acquisition of Domestic Commercialization Rights: This marketing authorization represents the transition from clinical development to commercial clearance, allowing the product to be officially sold in the South Korean market for the approved indication of rheumatoid arthritis.
• Domestic Approval Milestones: Having finalized the regulatory process approximately one year after the initial application in February 2024, the product has officially cleared the domestic administrative approval process.
• Key Post-Approval Milestones: To assess the timeline for actual market entry, the progression of domestic drug price determination, national health insurance listing, and the subsequent launch schedule in South Korea will serve as the areas for evaluation.

📝 Editor’s Comment (by K-STOCK Editor)

The final marketing authorization granted by the South Korean MFDS marks the completion of the regulatory review process required to transition CT-P47 from development into the domestic market. Securing approval for the subcutaneous formulation establishes the necessary legal baseline for commercial operations for the rheumatoid arthritis indication.

With the regulatory clearance achieved, the focus of future evaluation shifts toward the milestones required for commercial launch. The timeline for localized pricing determinations and national reimbursement listing by local authorities will be key factors in determining the initial commercial launch timeline in South Korea.

Going forward, key parameters to monitor include the official launch schedule in the domestic market, the finalized reimbursement price level, and the subsequent clinical adoption rates.

📢 Disclaimer & Source Information

Source: This content has been newly structured and written based on official disclosure data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.